These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 9720630

  • 1. In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist.
    Kohara A, Okada M, Tsutsumi R, Ohno K, Takahashi M, Shimizu-Sasamata M, Shishikura J, Inami H, Sakamoto S, Yamaguchi T.
    J Pharm Pharmacol; 1998 Jul; 50(7):795-801. PubMed ID: 9720630
    [Abstract] [Full Text] [Related]

  • 2. YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
    Takahashi M, Kohara A, Shishikura J, Kawasaki-Yatsugi S, Ni JW, Yatsugi S, Sakamoto S, Okada M, Shimizu-Sasamata M, Yamaguchi T.
    CNS Drug Rev; 2002 Jul; 8(4):337-52. PubMed ID: 12481190
    [Abstract] [Full Text] [Related]

  • 3. YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist.
    Shimizu-Sasamata M, Kawasaki-Yatsugi S, Okada M, Sakamoto S, Yatsugi S, Togami J, Hatanaka K, Ohmori J, Koshiya K, Usuda S, Murase K.
    J Pharmacol Exp Ther; 1996 Jan; 276(1):84-92. PubMed ID: 8558460
    [Abstract] [Full Text] [Related]

  • 4. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO, Varming T, Mathiesen C, Jensen LH, Moller A, Gouliaev AH, Wätjen F, Drejer J.
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [Abstract] [Full Text] [Related]

  • 5. Characterization of YM90K, a selective and potent antagonist of AMPA receptors, in rat cortical mRNA-injected Xenopus oocytes.
    Okada M, Kohara A, Yamaguchi T.
    Eur J Pharmacol; 1996 Aug 15; 309(3):299-306. PubMed ID: 8874154
    [Abstract] [Full Text] [Related]

  • 6. Effects of glutamate receptor agonists and antagonists on Ca2+ uptake in rat hippocampal slices lesioned by glucose deprivation or by kainate.
    Alici K, Gloveli T, Schmitz D, Heinemann U.
    Neuroscience; 1997 Mar 15; 77(1):97-109. PubMed ID: 9044378
    [Abstract] [Full Text] [Related]

  • 7. Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes.
    Stein E, Cox JA, Seeburg PH, Verdoorn TA.
    Mol Pharmacol; 1992 Nov 15; 42(5):864-71. PubMed ID: 1279377
    [Abstract] [Full Text] [Related]

  • 8. LU 73068, a new non-NMDA and glycine/NMDA receptor antagonist: pharmacological characterization and comparison with NBQX and L-701,324 in the kindling model of epilepsy.
    Potschka H, Löscher W, Wlaź P, Behl B, Hofmann HP, Treiber HJ, Szabo L.
    Br J Pharmacol; 1998 Nov 15; 125(6):1258-66. PubMed ID: 9863655
    [Abstract] [Full Text] [Related]

  • 9. Comparative patch clamp studies on the kinetics and selectivity of glutamate receptor antagonism by 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) and 1-(4-amino-phenyl)-4-methyl-7,8-methyl-endioxyl-5H-2,3-benzodiaze pine (GYKI 52466).
    Parsons CG, Gruner R, Rozental J.
    Neuropharmacology; 1994 May 15; 33(5):589-604. PubMed ID: 7523977
    [Abstract] [Full Text] [Related]

  • 10. Synthesis of 1,4,7,8,9,10-hexahydro-9-methyl-6-nitropyrido[3,4-f]- quinoxaline-2,3-dione and related quinoxalinediones: characterization of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (and N-methyl-D-aspartate) receptor and anticonvulsant activity.
    Bigge CF, Malone TC, Boxer PA, Nelson CB, Ortwine DF, Schelkun RM, Retz DM, Lescosky LJ, Borosky SA, Vartanian MG.
    J Med Chem; 1995 Sep 15; 38(19):3720-40. PubMed ID: 7562904
    [Abstract] [Full Text] [Related]

  • 11. 8-(1H-imidazol-1-yl)-7-nitro-4(5H)-imidazo[1,2-alpha]quinoxalinone and related compounds: synthesis and structure-activity relationships for the AMPA-type non-NMDA receptor.
    Ohmori J, Shimizu-Sasamata M, Okada M, Sakamoto S.
    J Med Chem; 1997 Jun 20; 40(13):2053-63. PubMed ID: 9207947
    [Abstract] [Full Text] [Related]

  • 12. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC, Guet T, Bobichon C, Moreau C, Curutchet P, Lambolez B, de Carvalho LP, Cordi A, Lepagnol JM.
    Mol Pharmacol; 1992 Feb 20; 41(2):337-45. PubMed ID: 1371583
    [Abstract] [Full Text] [Related]

  • 13. Are NMDA or AMPA/kainate receptor antagonists more efficacious in the delayed treatment of excitotoxic neuronal injury?
    Prehn JH, Lippert K, Krieglstein J.
    Eur J Pharmacol; 1995 Jan 13; 292(2):179-89. PubMed ID: 7720791
    [Abstract] [Full Text] [Related]

  • 14. Competitive inhibition by NBQX of kainate/AMPA receptor currents and excitatory synaptic potentials: importance of 6-nitro substitution.
    Randle JC, Guet T, Cordi A, Lepagnol JM.
    Eur J Pharmacol; 1992 May 14; 215(2-3):237-44. PubMed ID: 1382998
    [Abstract] [Full Text] [Related]

  • 15. N-methyl-D-aspartate/glycine and quisqualate/kainate receptors expressed in Xenopus oocytes: antagonist pharmacology.
    Verdoorn TA, Kleckner NW, Dingledine R.
    Mol Pharmacol; 1989 Mar 14; 35(3):360-8. PubMed ID: 2564633
    [Abstract] [Full Text] [Related]

  • 16. Novel AMPA receptor antagonists: synthesis and structure-activity relationships of 1-hydroxy-7-(1H-imidazol-1-yl)-6-nitro-2,3(1H,4H)- quinoxalinedione and related compounds.
    Ohmori J, Shimizu-Sasamata M, Okada M, Sakamoto S.
    J Med Chem; 1996 Sep 27; 39(20):3971-9. PubMed ID: 8831762
    [Abstract] [Full Text] [Related]

  • 17. AMPA- and kainate-receptors differentially mediate excitatory amino acid-induced dopamine and acetylcholine release from rat striatal slices.
    Jin S.
    Neuropharmacology; 1997 Sep 27; 36(11-12):1503-10. PubMed ID: 9517420
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology and regional distribution of the binding of 6-[3H]nitro-7-sulphamoylbenzo[f]-quinoxaline-2,3-dione to rat brain.
    Dev KK, Petersen V, Honoré T, Henley JM.
    J Neurochem; 1996 Dec 27; 67(6):2609-12. PubMed ID: 8931496
    [Abstract] [Full Text] [Related]

  • 19. Neuropeptide Y release from cultured hippocampal neurons: stimulation by glutamate acting at N-methyl-D-aspartate and AMPA receptors.
    Gemignani A, Marchese S, Fontana G, Raiteri M.
    Neuroscience; 1997 Nov 27; 81(1):23-31. PubMed ID: 9300398
    [Abstract] [Full Text] [Related]

  • 20. The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats.
    Nishiyama T, Gyermek L, Lee C, Kawasaki-Yatsugi S, Yamaguchi T.
    Anesth Analg; 1999 Jul 27; 89(1):143-7. PubMed ID: 10389792
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.